Exploring the Potential Molecular Mechanism of Sijunzi Decoction in the Treatment of Non-Segmental Vitiligo Based on Network Pharmacology and Molecular Docking

Du, Ziwei; Wang, Hepeng; Gao, Yang; Zheng, Shumao; Kou, Xiaoli; Sun, Guoqiang; Song, Jinxian; Dong, Jing‐fei; Wang, Genhui

doi:10.2147/ccid.s403732

Cited by 4 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of its high therapeutic value, bioactive compounds in SJZD have attracted much attention (Cui et al, 2021). Several studies have revealed the key targets of sarcopenia via network pharmacology analysis, such as AKT1, AIRT1, TNF, TP53 and PPARA (Cai et al, 2023;Du et al, 2023). In our network pharmacology study, 92 active compounds of SJZD against sarcopenia were acquired.…”

Section: Discussionmentioning

confidence: 91%

Exploring the therapeutic mechanisms of Sijunzi decoction in the treatment of sarcopenia: Key targets and signaling pathways

Dai,

Wang,

Jiang

et al. 2023

Biomedical Chromatography

View full text Add to dashboard Cite

Sarcopenia, an age‐associated condition, negatively impacts the quality of life. This study investigates the mechanism of Sijunzi decoction (SJZD), a traditional Chinese formula, against sarcopenia. Active compounds and potential targets of SJZD for sarcopenia were gathered from databases. Hub targets were identified using protein–protein interaction networks, with GO and KEGG analyses suggesting potential pathways. Molecular docking was used to assess compound–target affinity. A lipopolysaccharide‐induced sarcopenia rat model was used to verify the targets. Sijunzi decoction contains 92 compounds and 47 targets for sarcopenia. The top 10 hub targets comprise AKT1, ALB, INS, IL6, TNF, TP53, VEGFA, SIRT1, CAT and FOS. GO and KEGG analyses indicate involvement in steroid hormone response, vesicle lumen, receptor agonist activity, and FoxO and HIF‐1 signaling pathways. Validation experiments showed that SJZD alleviates sarcopenia by downregulating SIRT1, IL‐6, TNF and AKT1. Sijunzi decoction treats sarcopenia by targeting SIRT1, IL‐6, TNF and AKT1, potentially involving FoxO and HIF‐1 signaling pathways. This highlights SJZD’s potential for sarcopenia treatment.

show abstract

Section: Discussionmentioning

confidence: 91%

Exploring the therapeutic mechanisms of Sijunzi decoction in the treatment of sarcopenia: Key targets and signaling pathways

Dai,

Wang,

Jiang

et al. 2023

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Furthermore, investigations into specific compounds, such as kaempferol and quercetin, suggest their role in modulating PPARG expression and interacting with AKT1, pointing towards potential treatment avenues for endometrial cancer and nonsegmental vitiligo [ 22 , 23 ]. The relevance of these interactions extends to conditions like uric acid nephropathy, pneumonia, and type 2 diabetes mellitus, as demonstrated by studies using Xiezhuo Huayu Yiqi Tongluo Formula (XHYTF), Fritillariae thunbergii bulbus, and Alpinia officinarum Hance [ 24 – 26 ].…”

Section: Discussionmentioning

confidence: 99%

PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma

Han,

Chen,

Chen

et al. 2024

PPAR Research

View full text Add to dashboard Cite

It has been demonstrated that PPARG may interact with the PTEN-PI3K/AKT pathway, contributing to its involvement in the chemotherapy treatment of hypopharyngeal squamous cell carcinoma (HSCC). However, the underlying mechanism remains largely unknown. In this study, gene expression profiles of 17 HSCC patients, comprising 8 chemotherapy-sensitive patients (CSP) and 9 chemotherapy-nonsensitive patients (CNSP), were collected and analyzed to investigate expression patterns, correlations, influencing factors of the PPARG-PTEN-PI3K/AKT pathway, and its role in regulating chemosensitivity. The results revealed significantly increased expression (p<0.04) of AKT1, AKT2, AKT3, PIK3CA, PPARG, and PTEN in the CSP group compared to the CNSP group. Specifically, AKT2 exhibited significant overexpression in tumor tissue (p=0.01), while AKT2, AKT3, PPARG, and PTEN displayed significant increases in normal tissue (p≤0.04). Positive correlations (R∈0.43,0.71, p<0.014) were observed between PIK3CA, AKT1, AKT2, AKT3, and PTEN, with AKT2, AKT3, and PTEN also showing significant correlations with PPARG (R∈0.35,0.47, p<0.04). Age, gender, and disease stage had no influence on PPARG, PIK3CA, and PTEN expression, but they may affect AKT expressions. Pathway analysis revealed that PPARG may interact with the PTEN-PI3K/AKT signaling pathway, playing a crucial role in regulating chemosensitivity in the normal tissue microenvironment. Our results suggest that AKT1 and PIK3CA may be associated with chemosensitivity in HSCC tumor cells, while PPARG and PTEN might exhibit a correlation with a specific segment of the PI3K/AKT pathway, potentially influencing chemosensitivity in the normal tissue microenvironment of HSCC patients.

show abstract

Efficacy and safety of fire needle therapy in treating non‐segmental stable vitiligo: A randomized self‐controlled clinical trial

Wang,

Lin,

Huang

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundVitiligo remains a challenging condition to treat. Fire needle therapy, a traditional Chinese medicine technique, has potential as an alternative therapeutic strategy. However, rigorous evidence on its efficacy is lacking.ObjectiveWe aimed to evaluate the efficacy and safety of fire needle therapy, alone and combined with topical tacrolimus ointment, for non‐segmental stable vitiligo.MethodsIn this 6‐month randomized self‐controlled trial, 35 vitiligo patients were enrolled, providing three similar lesions each. Lesions were randomly allocated to receive fire needle monotherapy, 0.1% tacrolimus ointment monotherapy, or combined fire needle and tacrolimus ointment therapy. The main outcome was change in vitiligo surface area.ResultsIn total, 29 patients completed the 6‐month follow‐up. The combination therapy group showed significantly greater reductions in vitiligo surface area compared to monotherapy groups starting at months 4 and 5. By the end of the study, combination therapy resulted in remarkably higher repigmentation responses, with 89.7% of lesions showing at least mild (≥25%) repigmentation and 51.7% showing good (≥50%) repigmentation. This significantly exceeded the outcomes with topical tacrolimus ointment alone, which only achieved 6.9% mild response and 6.9% good response. Fire needle monotherapy also demonstrated steady repigmentation over time, with 69% of lesions attaining a mild response by month 6. Importantly, no major adverse events occurred.ConclusionThis study provides promising preliminary evidence supporting the use of fire needle therapy, alone or in combination with topical tacrolimus ointment, for inducing repigmentation in non‐segmental stable vitiligo. As a non‐pharmacological approach, fire needle therapy warrants further study as an alternative vitiligo treatment.

show abstract

Exploring the Potential Molecular Mechanism of Sijunzi Decoction in the Treatment of Non-Segmental Vitiligo Based on Network Pharmacology and Molecular Docking

Cited by 4 publications

References 62 publications

Exploring the therapeutic mechanisms of Sijunzi decoction in the treatment of sarcopenia: Key targets and signaling pathways

Exploring the therapeutic mechanisms of Sijunzi decoction in the treatment of sarcopenia: Key targets and signaling pathways

PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma

Efficacy and safety of fire needle therapy in treating non‐segmental stable vitiligo: A randomized self‐controlled clinical trial

Contact Info

Product

Resources

About